Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726876 | 0.88 | SMN1; SMN2 (0.48) | MTTPALDH1A1RAB9ANPC1 | |
| SCHEMBL3737492 | 0.88 | MTTP (0.52) | MTTPALDH1A1 | |
| SCHEMBL14031576 | 0.83 | MTTP (0.51) | MTTPALDH1A1 | |
| SCHEMBL3730614 | 0.83 | MTTP (0.44) | MTTPALDH1A1 | |
| SCHEMBL3727582 | 0.82 | MTTP (0.48) | MTTPALDH1A1 | |
| SCHEMBL27622150 | 0.82 | SMN1; SMN2 (0.47) | MTTPALDH1A1RAB9ANPC1 | |
| SCHEMBL6261203 | 0.81 | MTTP (0.62) | MTTPALDH1A1 | |
| SCHEMBL3727747 | 0.81 | PDK2 (0.39) | MTTPCYP1A2RAB9ANPC1 | |
| SCHEMBL3726100 | 0.81 | MTTP (0.52) | MTTPALDH1A1 | |
| SCHEMBL3725290 | 0.80 | MTTP (0.41) | MTTPALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075367-A1 | Ester compound and medicinal use thereof | LIPC, CES1, MTTP | MTTP 3/4885ALDH1A1 564/4885CYP1A2 450/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | MTTP 3/4885ALDH1A1 603/4885CYP1A2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.